Shares of Divi’s Laboratories surged nearly 5 per cent to touch a 52-week high of ₹8,500 on the NSE on Monday morning, as investors reacted to the pharma major’s strong first-quarter results declared on Saturday’s board meeting. At 11.29 am, the stock was trading at ₹8,454.50, up ₹398.50 or 4.95 per cent, with buy orders outpacing sell orders 56:44. Traded value had already crossed ₹886 crore, pushing the company’s market capitalisation to over ₹2.24 lakh crore.The stock has now gained over 25 per cent in the past month alone and 33 per cent year-to-date, significantly outperforming the Nifty Next 50 index, of which it is a constituent.Brokerages were broadly bullish following the Q1FY27 print. JM Financial retained its Buy rating with a target of ₹9,799, calling it a “blockbuster quarter” with revenue, EBITDA and PAT beating Street estimates by 12 per cent, 43 per cent and 39 per cent respectively. Citi raised its target sharply to ₹11,700, citing strong custom synthesis momentum and an EBITDA margin expansion of over 10 percentage points year-on-year to 40.7 per cent. Jefferies upgraded its target to ₹10,200, flagging a healthy beat driven by 50 per cent year-on-year growth in the custom synthesis segment. JPMorgan maintained Overweight with a ₹9,100 target, noting the quarter as a strong indicator of earnings potential as large synthesis programmes move toward commercial supply. Goldman Sachs recommended Accumulate, raising its target to ₹9,070.The lone dissent came from Kotak Institutional Equities, which kept a Sell rating with a revised target of ₹6,925, cautioning that the quarterly gross margin surge of 750 basis points may not be fully sustainable given the lumpy nature of validation batch supplies, and flagging stretched valuations at 37x FY28 EV/EBITDA.The company’s consolidated revenue from operations for the quarter ended June 30, 2026 stood at ₹3,080 crore, with profit after tax at ₹902 crore, against ₹545 crore in the year-ago period.Published on August 3, 2026